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The Effect of Enamel Matrix Derivative (Emdogain)
on Bone Formation: A Systematic Review
Florian Rathe, Dr. med. dent.,1 Ru¨diger Junker, Dr. med. dent., M.Sc.,1 Betsy M. Chesnutt, M.Sc.,1,2
and John A. Jansen, D.D.S., Ph.D.1
This systematic review focused on the question, if and to what extent enamel matrix derivative (Emdogain
[EMD]) promotes the regeneration of bone. The influence of combinations with other biomaterials was addi-
tionally evaluated. Twenty histomorphometric studies were included in this systematic review. Main results of
the reviewed articles were (i) guide tissue regeneration (GTR) of infrabony defects seems to result in a higher
degree of bone regeneration compared to treatment with EMD; (ii) combined therapy (GTRþEMD) of infrabony
defects might not lead to better results than GTR therapy alone; (iii) there seems to be no additional benefit of
combined therapy (GTRþEMD) in furcation defects over GTR therapy alone; (iv) EMD seems to lead to more
bone regeneration of infrabony defects compared to open flap debridement; (v) however, EMD application
might result in more bone formation when applied in supporting defects compared to nonsupporting defects;
and (vi) EMD does not seem to promote external jaw=parietal bone formation in the titanium capsule model. The
results of one study that suggest that EMD increases the initial growth of trabecular bone around endosseous
implants by new bone induction need to be confirmed by additional research.
Introduction
Periodontal regeneration is defined as the repro-duction or reconstruction of lost or injured tissue so that
the form and function of the lost structures are restored. In
order to fulfill the criteria set by the American Academy of
Periodontology,1 periodontal regeneration has to include re-
generation of cementum, functionally aligned periodontal
ligament, alveolar bone, and gingiva.
Histological findings and clinical results are suggestive
that regeneration of root cementum, periodontal ligament,
and alveolar bone can in fact occur in human infrabony de-
fects resulting from chronic periodontitis.2,3
Several studies have demonstrated that the use of enamel
matrix derivative (Emdogain[EMD]), a commercially avail-
able purified acidic extract from porcine enamel matrix
containing the hydrophobic protein assembly of amelogen-
ins, in periodontal regenerative surgery appears to favor the
formation of new attachment characterized by the presence
of new acellular and=or cellular cementum with inserting
collagen fibers and new alveolar bone.4–9 However, alveolar
bone formation following the use of EMD has been reported
to be minimal in spite of the presence of significant amounts
of new cementum.5,10,11 Up to now, the effect of EMD on
bone formation is not well understood.
In vivo, EMD stimulates bone regeneration of rat femurs,12
and it accelerates new bone formation in rat skull defects13;
further, it has been shown that it contains both transforming
growth factor– and bone morphogenetic protein–like growth
factors that contribute to the induction of mineralization
during periodontal regeneration.14 However, EMD failed to
show any significant benefit in promoting new bone forma-
tion around titanium implants in rabbits.15 This system-
atic review focuses on the question, if and towhat extent EMD
promotes the regeneration of bone. The influence of combi-
nations with other biomaterials was additionally evaluated.
Materials and Methods
Search strategy
A systematic literature search in electronic databases
(PubMed and Cochrane Library) was conducted, using the
following search term combination: ‘‘(emdogain OR EMD
OR enamel matrix derivative OR enamel matrix proteins)
AND (bone formation OR bone regeneration OR new bone
formation OR osteogenesis).’’
Further, a manual search in the references of the selected
papers was performed, focusing on articles related to the
effect of EMD on bone regeneration.
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Inclusion criteria
A literature search was performed to identify meta-analysis,
systematic reviews as well as randomized-controlled clinical
trials (RCTs), case reports, or case series.
Publications were considered for systematic review, if they
were published until June 2007 in English language and lis-
ted in the electronic databases, PubMed or Cochrane Library,
or were listed as reference in selected articles.
All articles had to provide histomorphometric data con-
cerning the question if and to what extent EMD affects bone
regeneration.
Selection of studies
Titles and abstracts of the publications identified by elec-
tronic databases were screened initially by two reviewers
(F.R. and R.J.). Publications were included for full-text eval-
uation if the content of the abstracts met the inclusion criteria
and matched to the focused question. Disagreement between
the reviewers was resolved by evaluation of the full texts and
discussion. Final authority for selection disagreements rested
with R.J. Full-text assessment was performed by the re-
viewers without any disagreements. A manual search was
performed among the references of the selected publications
after full-text assessment.
Exclusion criteria
Publications were excluded if they did not meet the in-
clusion criteria (i.e., no histomorphometric analysis per-
formed), or evaluated osteoinductive properties of EMD (i.e.,
ectopic bone formation), or did not provide relevant data for
the focused question. Excluded studies and reasons for ex-
clusion are listed in Table 1.
Results
Twenty studies were included for systematic review;
studies were summarized in Tables 2 and 3. Of these
20 studies, 5 reported on human data. Three of these were
case reports,10,16,17 and two were RCTs.5,11 The remaining
15 studies reported on data obtained from animal studies.
Results from human studies
The postoperative protocol was the same in three stud-
ies5,10,11 and consisted of 1 g amoxicillin per day for 1 week
postsurgery; patients were not allowed to perform oral hy-
giene at the surgical sites for 4 weeks and were instructed to
rinse twice per day with 0.2% chlorhexidine mouth rinse
during that time. Subsequently, professional prophylaxis
was performed once every second week during the entire
Table 1. Studies Excluded from Systematic Review
Study Subjects Sites investigated Reason for exclusion
Bosshardt et al.9 Human Periodontal infrabony defects No histomorphometry performed
Gurinsky et al.56 Human Periodontal infrabony defects No histomorphometry performed
Mellonig4 Human Periodontal infrabony defects No histomorphometry performed
Sculean et al.51 Human Periodontal infrabony defects No histomorphometry performed
Yukna and Mellonig8 Human Periodontal infrabony defects No histomorphometry performed
Boyan et al.59 Animal Mouse calf muscle Ectopic bone formation investigated
Donos et al.58 Animal Calvarial defects No histomorphometry performed
Donos et al.57 Animal Rat pectoralis profundi muscle Ectopic bone formation investigated
Kanazashi et al.55 Animal Periodontal buccal dehiscence defects No bone formation investigated
Kawana et al.12 Animal Rat femur No histomorphometry performed
Koike et al.54 Animal Rat rectus abdominis muscle Ectopic bone formation investigated
Nemcovsky et al.53 Animal Periodontal intra-suprabony defects Mostly suprabony defects
Sculean et al.52 Animal Fenestration-type defects Defects healed spontaneously in all groups
Yoneda et al.13 Animal Rat skull defect No histomorphometry performed
Table 2. Studies Reporting on Human Data
Study Type of defect
Sample size
(number of
defects)
Treatment
groups
Results
(mm of new bone
formation=%
of defect fill with
new bone)
Histology
performed
(time allowed
for healing)
Heijl16 Periodontal buccal
dehiscence
n¼ 1 EMD 65% 4 months
Majzoub et al.17 Periodontal infrabony n¼ 1 EMD 3.63mm 9 months
Sculean et al.5 Periodontal infrabony n¼ 14 G1: EMD 0.9 1.0mm 6 months
G2: GTR 2.1 1.0mm
Sculean et al.10 Periodontal infrabony n¼ 2 EMD 0 and 1.7mm 6 months
Windisch et al.11 Periodontal infrabony n¼ 14 G1: EMD 0.78 0.97mm 6 months
G2: GTR 1.93 1.04mm
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Table 3. Studies Reporting on Animal Data
Study
Type
of defect
Sample size
(number of
defects) Treatment groups
Results (mm of
new bone formation=%
of defect fill with
new bone)
Histology
performed
(time allowed for
healing)
Casati et al.26 Implant
buccal
dehiscence
n¼ 48 G1: EMD 55.55 11.81%
NBA
3 months
G2: EMDþGBR 62.15 18.47%
NBA
G3: GBR 53.89 16.35%
NBA
G4: negative control 36.95 25.10%
NBA
Cochran et al.18 Periodontal
infrabony
n¼ 40 G1: EMD in 1-mm-wide
defects
2.86mm 5 months
G2: OFD in 1-mm-wide
defects
2.48mm
G3: EMD in 2-mm-wide
defects
3.14mm
G4: OFD in 2-mm-wide
defects
2.11mm
G5: EMD in 4-mm-wide
defects
1.22mm
G6: OFD in 4-mm-wide
defects
1.78mm
G7: EMD in 6-mm-wide
defects
2.01mm
G8: OFD in 6-mm-wide
defects
1.89mm
Donos et al.23 Class III
furcation
n¼ 12 G1: EMD 71.95 21.3% 5 months
G2. EMDþGTR 73.3 11.8%
G3: GTR 59.8 32.5%
G4: CAF 43.9 6.1%
Donos et al.28 PTFE
capsule
n¼ 16 G1: capsuleþEMD 17.5% 120 days
G2: capsuleþDBBM 15.1%
G3: capsuleþEMD
þDBBM
12.0%
G4: capsule 39.7%
Fernandes et al.24 Class III
furcation
n¼ 20 G1: EMDþGTR 0.1 0.3% 90 days
G2: EMDþGTRþBG 2.0 2.9%
G3: GTRþBG 0.8 1.7%
Hammarstro¨m et al.21 Periodontal
buccal
dehiscence
n¼ 94 G1: homog. enamel
matrix
54% 8 weeks
G2: amelogenin 73%
G3: enamelin 0%
G4: EMD 67%
G5: OFD 2%
Murai et al.29 Calvarial n¼ 28 G1: capþ b-TCPþEMD 42.2 13.1% 1 month
G2: capþ b-TCP 36.8 10.3%
G1: capþ b-TCPþEMD 43.3 6.8% 3 months
G2: capþ b-TCP 41.2 10.6%
Onodera et al.19 Periodontal
infrabony
n¼ 24 G1: GTR 55.2 0.1% 4 weeks
G2: GTRþEMD 77.6 0.2%
G1: GTR 90.1 0.12% 8 weeks
G2: GTRþEMD 98.3 0.04%
Regazzini et al.25 Class II furcation n¼ 24 G1: EMD 67.36 3.93% 8 weeks
G2: EMDþGTR 28.49 10.32%
G3: OFD 31.65 6.06%
(Continued)
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study period. One study did not provide information about
performed postoperative care,16 and one study reported the
use of 200mg doxycycline per day for 10 days postsurgery.17
The patient of this case report was instructed to rinse with
0.2% chlorhexidine three times daily for 6 weeks following
surgery; the patient was recalled monthly for professional
supragingival plaque control during the first 6 months
postoperatively and every 3 months thereafter.
One buccal dehiscence defect in one case report16 was
surgically created. All other defects resulted from chronic
periodontitis, and patients received full mouth scaling and
root planing under local anesthesia 3 months prior to sur-
gical procedures.
In two case reports, 37% orthophosphoric acid was applied
for 15 s for root conditioning prior to application of EMD,16,17
whereas 24% ethylenediaminetetraacetic acid (EDTA) was
administrated for 2min in the other three studies.5,10,11
Clinical healing was uneventful in all defects of all studies
throughout the study periods, and no subjective adverse
experiences were recorded.
New bone formation after treatment and the time point of
histomorphometry are presented in Table 2.
In one case report,16 a buccal dehiscence defect was cre-
ated surgically at tooth 31 of a 49-year-old nonsmoking male
and extended from the mesial to the distal line angle (at the
line angle, the flat tooth surface converts into the curvature)
and was almost reaching the apex (exact defect size is not
mentioned).
Majzoub et al.17 reported on treatment with EMD of a
mandible first molar of a 46-year-old woman presenting with
a deep infrabony defect. The intraoperative morphology of
the defect at the distal root demonstrated a deep infrabony
circumferential defect involving all four surfaces of the root
with an infrabony component of 8.5mm; further, the tooth
presented a trough and through furcation involvement. Two
distinct healing patterns were evident 9 months after EMD
treatment. At the distal surface of the distal root, new bone
extended 3.63mm coronal to the reference notch, which
seemed to parallel cementum deposition throughout most of
the defect, whereas an ankylosis was present at the furcal
surface.
Two combined one- and two-walled advanced infrabony
defects (maxillary left central incisor) had been treated with
EMD in two patients aged 50 and 55 years in the third case
report reviewed.5
Both RCTs5,11 evaluated periodontal regeneration of
advanced infrabony defects following the treatment with
EMD or guided tissue regeneration (GTR) using bioabsorb-
able membranes (Resolut). Fourteen infrabony defects were
treated in each study, which were equally distributed to
each group in the study from Sculean et al.5 In the study of
Windisch et al.,11 eight defects were treated with GTR pro-
Table 3. (Continued)
Study
Type
of defect
Sample size
(number of
defects) Treatment groups
Results (mm of
new bone formation=%
of defect fill with
new bone)
Histology
performed
(time allowed for
healing)
Sallum et al.22 Periodontal buccal
dehiscence
n¼ 24 G1: EMD 2.01 0.82mm 4 months
G2: GTR 0.91 1.08mm
G3: EMDþGTR 1.40 1.08mm
G4: OFD 1.14 0.39mm
Sawae et al.30 Parietal n¼ 10 G1: EMD 0.97 0.04% 60 days
G2: PGA 0.74 0.17%
Sculean et al.6 Periodontal
infrabony
n¼ 24 G1: EMD 1.4 0.9mm 5 months
G2: GTR 2.0 1.1mm
G3: EMDþGTR 2.1 1.1mm
G4: CAF 0.7 1.1mm
Shimizu et al.27 Bone-to-implant
contact
n¼ 10 G1: EMD 12.82 1.42%a 30 days
G2: PGA 9.88 2.31%a
Shirakata et al.20 Periodontal
infrabony
n¼ 16 G1: a-TCP 3.58 0.79mm 10 weeks
G2: a-TCPþEMD 3.07 0.62mm
G3: EMD 2.33 0.92mm
G4: OFD 1.95 0.8mm
Stenport and
Johansson15
Bone-to-implant
contact
n¼ 36 G1: EMD 10 8% BMC 6 weeks
G2: PGA 12 3% BMC
G1: EMD 53 16% NBA
G2: PGA 58 11% NBA
G1: EMD 4.5 2.0% BL
G2: PGA 6.0 1.8% BL
a% of newly formed trabecular bone=medullary cavity after 30 days.
BG, bioactive glass; CAF, coronal advanced flap; BMC, bone-to-metal contact; BL, bone length.
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cedure and six with the use of EMD. Further, all patients
were nonsmokers in the study of Sculean et al.,5 whereas one
smoker was treated with GTR procedure and two smokers
were treated with EMD in the investigation of Windisch
et al.11 No membrane exposure was noted in either study.
Both studies found a significant difference in new bone for-
mation favoring the GTR treatment (Table 2). In 5 out of 13
specimens, no new bone formation could be evaluated his-
tologically after EMD treatment; further, bone regeneration
was minimal (0.2–0.5mm) in four further defects. In the re-
maining four defects of the EMD group, bone regeneration
could be evaluated with a range of 1.8–2.2mm. Infrabony
defects treated with GTR showed at least minimal bone for-
mation (0.1 and 0.2mm) in 2 defects, whereas the 12 remain-
ing defects showed bone regrowth within a range of 1–3mm.
Results from animal studies
Infrabony and dehiscence defects. All studies mentioned
here investigated standardized periodontal infrabony6,18–20
or dehiscence-type21,22 defects, either in monkeys6,18,21 or
dogs.19,20,22 In four studies,6,18,19,22 ligature-induced inflam-
mation was provoked after surgical defect creation to prevent
spontaneous healing. In all studies, the postoperative protocol
comprised the administration of antibiotics, whereas plaque
control was only performed in four studies after regenera-
tive therapy.6,19,20,22 In most studies, root conditioning was
only performed when EMD was applied.6,18–20,22 Three
studies19–21 used phosphoric acid (concentration varied be-
tween 35% and 37% for 15 s), and all other studies6,18,22 used
EDTA-gel (concentration 24% for 2min).
The sample size, type of defect, treatment modality, re-
sults, and time allowed for healing are presented in Table 3
for all studies reporting on animal data.
In the studies of Sculean et al.6 and Onodera et al.,19 in-
frabony defects of approximately 6- to 8-mm depth were
created, but no information was given about the amount of
bony walls. While reading the surgical procedure, one can
assume that one- or two-wall defects were created. For the
GTR procedure, either bioresorbable barrier membrane (Re-
solute6) or nonresorbable extended-polytetrafluorethylene
(e-PTFE) membrane (Gore-Tex19) was used.
In the study of Sculean et al.,6 a great amount of sites
experienced membrane exposure; two sites (one of the GTR
group and one of the GTRþEMD group) had to be excluded
from histological evaluation because of early membrane ex-
posure during the second postoperative week. Another site
from the GTR group had to be excluded due to failure dur-
ing histological processing. There were four additional sites
showing membrane exposure in the third postoperative
week (two of the GTR group and two of the GTRþEMD
group). Those four sites were not excluded from histological
evaluation, so that only two out of the four evaluated sites in
the GTR group and three out of five sites of the GTRþEMD
group experienced no membrane exposure. Even so, the most
new bone formation was detected after the use of a barrier
membrane.
No postoperative membrane exposure is mentioned in the
study by Onodera et al.19 In this study, no bone formation
was evident 1 week after regenerative surgery in either
group, but 2 (results not shown) and 4 weeks after surgery,
significantly more bone formation ( p < 0.05) could be de-
termined in the combined group (GTRþEMD, Onodera
et al.19). However, 8 weeks postsurgery, no significant dif-
ferences could be found between the two treatment groups.
The healing of standardized one-wall periodontal defects
of 554mm20 and defects of standardized depth with
varying width in the mesiodistal direction18 was investigated
in two further studies. Shirakata et al.20 found no significant
differences between EMD (G3) and open flap debridement
(OFD) (G4) groups or between the EMDþ a-tricalcium
phosphate (TCP) (G2) and a-TCP (G1) groups (Table 3).
However, if G3 and G4 are compared with G1 and G2 (G4
vs. G1 or G2, p< 0.0001; G3 vs. G1, p< 0.0001; G3 vs. G2,
p¼ 0.0057), significantly more bone formation was deter-
mined in the EMDþ a-TCP (G2) and a-TCP (G1) groups. The
study of Cochran et al.18 showed that EMD applied in nar-
row defects (1- and 2-mm-wide defects) resulted in 3.00-mm
new bone compared to 2.29mm of new bone for the control
treatment, a 31% increase in bone height. In wider lesions (4-
and 6-mm-wide defects), the amount of new bone was sim-
ilar between EMD-treated sites and controls (1.67 and
1.84mm).
Buccal dehiscence defects in both studies were approxi-
mately 6-mm deep,21,22 whereas the width of the defect
(4mm) was only mentioned in the article by Sallum et al.22 In
the study by Hammarstro¨m et al.,21 which was performed to
explore the effect of locally applied enamel matrix and dif-
ferent protein fractions of the matrix on periodontal regen-
eration, it was shown that it is possible to obtain regeneration
of 54–73% of bone tissues by applying the whole enamel
matrix, the acid extract (amelogenin), or EMD in the buccal
dehiscence model. Sallum et al.22 utilized nonresorbable
barrier membranes (Resolute) for the GTR procedure, and
only one membrane of the EMDþGTR group experienced
exposure in the first postoperative week. Regarding new
bone formation, no statistically significant differences were
observed among the groups (Table 3).
Furcation defects. Different regenerative procedures
(Table 3) were evaluated in standardized furcation defects in
monkeys23 and dogs.24,25 Two studies investigated class III
furcation involvement with a vertical dimension of 3–4mm23
and 5mm.24 Regazzini et al.25 created class II furcation de-
fects with a vertical dimension of 5mm and a horizontal
component of 2mm, which equals a class II furcation in
dogs. Plaque formation with subsequent inflammation of the
defect was provoked in all studies after surgical defect cre-
ation. Following regenerative surgery antibiotics were ad-
ministered in all investigations, as well as plaque control
regiments. Root conditioning was performed only in com-
bination with EMD treatment in two studies,23,24 whereas
root surfaces of the control defects also received root condi-
tioning in the trial of Regazzini et al.25 EDTA-gel (24%) ap-
plied for 2min was used in all studies for root conditioning.
Resorbable membranes (Resolute23 and Resolute XT24)
were utilized in two studies, and nonresorbable e-PTFE
barrier membranes (Gore-Tex) were used in one study.25
Membranes were exposed 15 days after surgery in the
study of Regazzini et al.,25 but no information about the
amount of exposed membranes was provided. No significant
difference in terms of new bone formation was evident be-
tween the EMDþGTR group and the control treatment, but
EMD treatment alone resulted in significant more bone
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formation ( p< 0.05) compared to groups EMDþGTR and
OFD (for results see Table 3). In the experimental trial of
Donos et al.,23 exposure of the membrane occurred in two
sites treated with GTR alone during the second postoperative
week. In the third postoperative week, a defect treated with
the combination of GTR and EMD presented exposure of the
membrane. Additionally, one defect treated with EMD ex-
perienced recession of the flap to the level of the fornix of the
furcation (for results see Table 3). No postoperative mem-
brane exposure was mentioned in the study by Fernandes
et al.24 Statistical analysis of the treatment outcome did not
show significant differences among the different groups for
linear and area measurements; however, it must be pointed
out that no negative control group (e.g., OFD) was evaluated
(for results see Table 3).
Periimplant defects and bone-to-implant contact. Casati
et al.26 created buccal dehiscence defects (3.55.0mm) in dogs
before and 2 months after implant (3.758.5mm; screw-
shaped pure titanium) placement. The buccal dehiscence de-
fects were treated with various regenerative procedures (Table
3; Resolute XT was used for guided bone regeneration [GBR]),
and the postoperative protocol consisted of administration of
antibiotics and daily plaque control until the animals were
sacrificed. The percentage of bone-to-implant contact and new
bone area (NBA) within the limits of the previously exposed
threads of each implant were determined. After 3 months, no
statistically significant differences were observed among the
groups in terms of bone-to-implant contact (results not
shown). However, the EMDþGBR group presented a greater
( p< 0.05) area of new bone when compared to the control
group. The groups treated by EMD or GBR alone showed no
statistically significant differences in NBA when compared to
controls or to the EMDþGBR group (Table 3). Thirty-six
screw-shaped pure titanium implants (3.758.0mm) were
placed in rabbit femurs in the study by Stenport and Jo-
hansson.15 Immediately prior to implant insertion, either EMD
or its vehicle gel (propylene glycol alginate [PGA]) alone was
placed into the surgically created implant site. The percentage
of bone-to-metal contact and bone area were measured in all
threads as well as the entire bone length along the implant
surface, but the differences were not statistically significant.
Shimizu et al.27 inserted cylinder-shaped mini titanium im-
plants (1.63.5mm) with filling of medullary cavities with
either EMD or its carrier. Mean percentage of newly formed
trabecular bone per medullary cavity was assessed. In mor-
phometric analysis, newly formed trabecular bone area within
medullary cavities was significantly ( p< 0.05) greater in
EMD-treated femurs than in PGA-treated femurs 30 days
postimplantation.
Bone formation in experimental capsule and parietal
model. Donos et al.28 placed hemispherical PTFE capsules
(internal diameter: 5mm and wall thickness: 0.5mm) with
openings facing the lateral aspect of the mandible ramus of
Wistar rats. The animals were randomly allocated to four
treatment groups (Table 3). Percentage of newly formed bone
of the maximal possible space created by the capsule was
determined by planimetric measurements. The PTFE capsule
had been slightly displaced during healing in three out of
five specimens of group 1, in one out of three of group 2, in
three out of four of group 3, and in two out of five in group 4
(Table 3), which resulted in a less-favorable treatment out-
come compared to those capsules that had not been dis-
placed. Statistically significant differences could be evaluated
between capsule-alone group and capsuleþdeproteinized
bovine bone mineral (DBBM) ( p¼ 0.034) and capsuleþ
DBBMþEMD ( p¼ 0.021) groups, favoring the capsule-alone
group in terms of new bone formation. In other words, there
was no significant difference between capsule-alone group
and capsuleþEMD, whereas adding DBBM led to less-
favorable results. The PTFE capsule model has also been
utilized in rabbit calvarium by Murai et al.29 The capsules
were filled either with b-TCPþEMD or with b-TCP alone
(Table 3). After both 1 ( p¼ 0.075) and 3 months of healing
(Table 3; p¼ 0.92), no significant differences in the amount of
newly formed bone were found between test and control
capsules. Sawae et al.30 perforated the parietal bones of
Wistar rats with a sterile round bur (0.8-mm diameter). The
injured bone areas were immediately filled with EMD (test)
or its PGA-carrier (control) and allowed to heal for 4, 7, 14,
30, and 60 days. The results were expressed as the mean
percentages of newly formed bone areas per perforated space.
Morphometric analysis showed that at only 60 days post-
surgery, new bone formation in the EMD-treated parietal
bones was significantly ( p< 0.05) greater than that seen in
PGA-treated controls (Table 3).
Discussion
The aim of this systematic review was to evaluate the
osteopromotive properties of EMD in vivo, since it has not
been done before. Twenty studies were included for system-
atic review. Five reported on human data with three of these
being case reports and two being RCTs. The remaining
15 studies reported on data obtained from animal studies.
Unfortunately, none of the histomorphometric studies re-
porting on human data compared the amount of bone re-
generation in periodontal defects after the use of EMD with
a control surgery (i.e., OFD and coronal advanced flap). If
bone regrowth was evaluated after the use of EMD and
compared with results obtained after utilizing the GTR
therapy with resorbable membranes, GTR therapy resulted
in a higher degree of bone regeneration than treatment with
EMD (Table 25,10,11).
The amount of bone regrowth after the use of EMD in the
two cases reported by Sculean et al.10 is in accordance with
the minimal bone regrowth reported by Sculean et al.5 and
Windisch et al.11 Heijl16 published outstanding results with
respect to bone regeneration. He achieved a bone regrowth
of 65% of the presurgical bone height of a buccal dehiscence
defect reaching almost the apex. The discrepancy between
the results reported by Sculean et al.5,10 and Windisch et al.11
and the case of Heijl16 can be explained, at least in part, by
spontaneous healing, since the buccal dehiscence defect
treated by Heijl16 was of an acute type (i.e., defect was sur-
gically created and immediately treated without previous
plaque exposure period). Histological studies in monkeys
have shown that in acute defect models approximately 50–
70% spontaneous regeneration can be expected, which may
lead to difficulties in interpreting the results.31 Majzoub
et al.17 achieved a bone regrowth of 3.63mm in his case re-
port. This result is comparable to the outstanding result
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achieved by Heijl16 with the difference that the defect treated
by Majzoub et al.17 was not created surgically but resulted
from chronic periodontitis. Majzoub et al.17 reported that
bone regrowth appeared to parallel new cementum deposi-
tion, which is in contrast to the other publications5,10,11 re-
porting new bone formation to be minimal compared to
cementum deposition (results not shown).
Another interesting result reported byMajzoub et al.17 is the
ankylosis of the experimental tooth in the furcation area. It can
be speculated that the necrotizing effect of low-pHphosphoric
acid might have impaired the vitality and subsequently the
healing potential of precursor cells involved in cementum and
connective tissue formation, which resulted in ankylosis.32–34
Root surface conditioning has been conventionally performed
with 37% phosphoric acid with a pH value of one16,35,36
or with EDTA 24% at a neutral pH.37–41 Although it has been
shown that long-time etching at low pH jeopardizes peri-
odontal healing,32 the low pH of phosphoric acid does not
seem to impair bone regeneration when used according to the
published protocols.16,17
Regarding the distal infrabony defect, the flap supporting
the circumferential structure leading to wound stability could
be a possible explanation for the high amount of bone re-
growth achieved byMajzoub et al.,17 since results from animal
studies suggest that EMD results in less regeneration in non-
supporting defects.18,20
Due to its gel-like consistence, EMD has no space-
providing properties in order to avoid collapsing of the flap
into the defect in cases where anatomical structures do not
support the flap. However, this space provision seems to be a
prerequisite for bone regeneration.42
The results of Polimeni et al.42 seem to be supported by the
finding that EMD gives rise to more bone regrowth in
smaller-sized one-wall defects compared to larger-sized one-
wall defects.18 However, it should also be taken into account
that the bone crest was narrower and, hence, more resorbed
adjacent to the larger defects. As a result, the amount of
regeneration was likely influenced by the position of the
bone crest. In standardized nonsupporting one-wall defects,
no difference between treatment with EMD and OFD could
be determined. However, a statistically significant difference
of OFD was achieved after adding a space-providing a-TCP
cement to the EMD.20 Sculean et al.6 and Sallum et al.22 also
achieved more favorable results in terms of bone regrowth
when EMD was combined with a space-providing GTR
barrier membrane compared to EMD treatment alone. Dif-
ferences in the study of Sculean et al.6 were not statistically
significant, and combined treatment resulted in new bone
formation comparable to GTR therapy alone. Membrane
exposure and subsequent bacterial colonization and infection
were frequently occurring complications in this study, which
might explain why Sallum et al.22 found significantly better
results for the combined treatment compared to EMD alone
(only one exposed membrane). Surprisingly, Sallum et al.22
reported no difference between GTR alone and OFD. Inter-
estingly, Onodera et al.19 determined that in the combined
treatment procedure (GTRþEMD), EMD influenced new
bone formation positively during the first 4 weeks of healing
compared with GTR therapy alone, whereas no difference
was apparent after week 8 of healing.
When treatment of infrabony defects with EMD alone is
compared with OFD, most studies report significantly better
results for the EMD therapy.6,21,22 Unfortunately, supportive
or nonsupportive structure (i.e., amount of bony walls) as
well as the exact defect dimensions (width at the base of the
pocket in orobuccal dimension, width in mesiodistal di-
mension, and height of the defect) are not reported in these
articles, which makes it difficult to draw conclusions on the
influence of anatomical factors.
Membrane exposure seemed to occur more frequently in
monkey6,23 than in dog models.19,22,24,26 A possible expla-
nation is that monkeys play with the sutures at the surgical
site, which jeopardizes primary healing. It has been shown
that membrane exposure with subsequent bacterial coloni-
zation and infection leads to a less-favorable treatment out-
come.43–47
Regazzini et al.25 reported significantly more new bone
formation when EMD was applied in class II furcation de-
fects, compared to OFD and the combined therapy (GTRþ
EMD). The authors of this study did not find a significant
difference between the combined treatment and OFD. An
explanation can be that membrane exposure is responsible
for the treatment outcome of the combined group; unfortu-
nately, the amount of sites that became exposed is not
mentioned and could be minimal since the study was per-
formed in dogs. The good treatment outcome for the EMD
group could indicate that space-providing barrier mem-
branes are not of major importance in class II furcation de-
fects, since the tooth roots prevent collapse of the flap. Donos
et al.23 reported most favorable results for the combined
therapy although differences to the EMD-alone group were
negligible in the treatment of class III furcation defects.
However, one out of three sites treated with the combined
therapy (GTRþEMD) experienced membrane exposure that
led to less-favorable results. The amount of new bone for-
mation of the GTR-alone group was located between the
other two test groups (GTRþEMD and EMD alone) and the
OFD group, but it has to be taken into account that two out
of three sites treated with GTR alone experienced membrane
exposure. In the GTR-treated defect where membrane was
not exposed, the defect had healed almost completely with
bone. Whereas in those sites where the membrane became
exposed, the amount of newly formed bone was minimal. On
the other hand, only one of the three furcation defects treated
with EMD alone had healed almost completely, which might
suggest that treatment of class III furcation defects with EMD
is unpredictable. In the assessment of bone fill in furcation
class III defects in dogs, minimal formation was observed,
limited to the basis of the defect in the three test groups
studied (Table 3) without any statistical difference between
the groups.24 However, the number of animals is a weak
point to be considered and a limitation to finding differences
among groups.
Stenport and Johansson15 concluded in their study that
EMD treatment does not contribute to bone formation
around titanium implants in a rabbit model. The authors
suggested that the model used was not ideal to study the
effects of bone-stimulating proteins because of the large
cortical area that had to be resorbed before osseointegration
could occur. This theory is supported by the findings of
Tonetti et al.,41 who reported in a clinical study that highly
cortical and highly cancellous bone types negatively im-
pacted the outcome of EMD treatment in infrabony defects.
In contrast, the results of Shimizu et al.27 suggest that EMD
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increases the initial growth of trabecular bone around en-
dosseous implants by new bone induction in the medullary
cavities and maintains such bony support of implants by
filling the surfaces with newly formed bone trabeculae.
These newly formed bone trabeculae were immunoactive for
bone sialoprotein (BSP), which is a noncollagenous bone ma-
trix protein, and were localized at the mineralization site of
developing bone.48 BSP-positive trabecular bone formed after
implantation is thought to be bone matrix produced by newly
differentiated osteoblasts,49 indicating that EMD promotes
osteogenic differentiation of pluripotent mesenchymal cells.
The results of Casati et al.26 also indicate that EMD positively
influences bone healing after GBR around titanium implants.
EMD alone, however, had no statistically significant effect.
The membrane could have provided a protected coagu-
lum and also helped to avoid collapse of the flap into the
dehiscence-type defect, supporting the results of Polimeni
et al.42
In contrast to the findings from Shimizu et al.,27 BSP was
only weakly observed in the newly formed trabecular bone
of parietal bone defects; however, 60 days postoperation,
new bone formation in EMD-applied defects was signifi-
cantly greater than that seen in PGA-applied controls.30
Using a Teflon capsule model, the study by Donos et al.28
failed to support the hypothesis that the adjunctive appli-
cation of EMD to GBR would positively influence the for-
mation of new jaw bone outside the skeletal envelope. This
finding is in accordance with the study by Murai et al.29 who
found no significant difference in promotion of new bone
formation between b-TCP alone, and the combination of
EMD and b-TCP within a titanium capsule, but in contrast to
observations in which a positive influence on bone formation
was seen following the application of EMD under a barrier
membrane.22,26
Conclusion
The findings of the studies should be considered with
caution due to the small sample sizes. Small numbers of
animals are frequently observed in the literature and are a
consequence of the limitations when testing on larger ani-
mals, such as dogs and monkeys. In addition, direct ex-
trapolation of data obtained from animal studies to humans
should be interpreted cautiously. Further, small sample sizes
and a lack of matching defects, due to obvious reasons, are
the limitations in human histological trials.
Another very important point that needs to be mentioned
is that the maximum time allowed for healing in the re-
viewed articles was 9 months, but bone regeneration seems
to continue to increase over 36 months after EMD treat-
ment.50 Thus, bone regrowth might not be completed at the
time of histological preparation.
The reviewed articles allow for the following conclusions:
Human studies have shown that GTR therapy of infrab-
ony defects seems to result in a higher degree of bone re-
generation than treatment with EMD. Animal studies
suggest that EMD seems to lead to more bone regeneration
of infrabony defects compared to OFD; however, EMD ap-
plication might result in more bone formation when applied
in supporting defects compared to nonsupporting defects.
Further, most animal studies suggest that combined therapy
(GTRþEMD) of infrabony defects might not lead to better
results than GTR therapy alone.
In animals, EMD seems to result in more bone formation
compared to OFD in both furcation class II and III defects, but
treatment of class III furcation defects with EMD is unpre-
dictable. Additionally, there seems to be no additional benefit
of combined therapy (GTRþEMD) in furcation defects.
EMD does not seem to promote external jaw=parietal bone
formation in the titanium capsule model.
EMD might increase growth of trabecular bone around
implants by new bone induction in the medullary cavities.
However, when bony defects adjacent to dental implants
have to be treated, combination with GBR procedures seems
to lead to better results compared to application of EMD
alone and GBR alone.
The cautious use of phosphoric acid for root conditioning
prior to EMD application does not seem to influence bone
regeneration negatively.
It might be suggested that EMD promotes osteogenic
differentiation of pluripotent mesenchymal cells in vivo.
Thus, EMD seems to promote bone formation, but the lack of
space-providing properties might be a limiting factor. Fur-
ther, an additional benefit of EMD in combination with a
space-providing GTR technique seems to be limited.
For future studies, it would be desirable to mention the
exact size of the infrabony defects because the width of
the defect base seems to be especially crucial for determining
the extent of bone regeneration.42 The amount of bony walls
should also be mentioned in order to allow for further con-
clusions and easier comparison between studies.
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